Single gene prognostic biomarkers in ovarian cancer: a meta-analysis
S Willis, VM Villalobos, O Gevaert, M Abramovitz… - PloS one, 2016 - journals.plos.org
PloS one, 2016•journals.plos.org
Purpose To discover novel prognostic biomarkers in ovarian serous carcinomas. Methods A
meta-analysis of all single genes probes in the TCGA and HAS ovarian cohorts was
performed to identify possible biomarkers using Cox regression as a continuous variable for
overall survival. Genes were ranked by p-value using Stouffer's method and selected for
statistical significance with a false discovery rate (FDR)<. 05 using the Benjamini-Hochberg
method. Results Twelve genes with high mRNA expression were prognostic of poor …
meta-analysis of all single genes probes in the TCGA and HAS ovarian cohorts was
performed to identify possible biomarkers using Cox regression as a continuous variable for
overall survival. Genes were ranked by p-value using Stouffer's method and selected for
statistical significance with a false discovery rate (FDR)<. 05 using the Benjamini-Hochberg
method. Results Twelve genes with high mRNA expression were prognostic of poor …
Purpose
To discover novel prognostic biomarkers in ovarian serous carcinomas.
Methods
A meta-analysis of all single genes probes in the TCGA and HAS ovarian cohorts was performed to identify possible biomarkers using Cox regression as a continuous variable for overall survival. Genes were ranked by p-value using Stouffer’s method and selected for statistical significance with a false discovery rate (FDR) <.05 using the Benjamini-Hochberg method.
Results
Twelve genes with high mRNA expression were prognostic of poor outcome with an FDR <.05 (AXL, APC, RAB11FIP5, C19orf2, CYBRD1, PINK1, LRRN3, AQP1, DES, XRCC4, BCHE, and ASAP3). Twenty genes with low mRNA expression were prognostic of poor outcome with an FDR <.05 (LRIG1, SLC33A1, NUCB2, POLD3, ESR2, GOLPH3, XBP1, PAXIP1, CYB561, POLA2, CDH1, GMNN, SLC37A4, FAM174B, AGR2, SDR39U1, MAGT1, GJB1, SDF2L1, and C9orf82).
Conclusion
A meta-analysis of all single genes identified thirty-two candidate biomarkers for their possible role in ovarian serous carcinoma. These genes can provide insight into the drivers or regulators of ovarian cancer and should be evaluated in future studies. Genes with high expression indicating poor outcome are possible therapeutic targets with known antagonists or inhibitors. Additionally, the genes could be combined into a prognostic multi-gene signature and tested in future ovarian cohorts.
PLOS